SCI Pharmtech Inc
TWSE:4119
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (31.6), the stock would be worth NT$98.63 (103% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.6 | NT$48.55 |
0%
|
| 3-Year Average | 31.6 | NT$98.63 |
+103%
|
| 5-Year Average | 32.1 | NT$100.29 |
+107%
|
| Industry Average | 11.4 | NT$35.5 |
-27%
|
| Country Average | 14.6 | NT$45.44 |
-6%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
S
|
SCI Pharmtech Inc
TWSE:4119
|
5.8B TWD | 15.6 | 54 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 28.5 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.4 | 29.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.5 | 20.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 9.9 | 15.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.2 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 7.7 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0.8 |
| 30th Percentile | 10.5 |
| Median | 14.6 |
| 70th Percentile | 22.8 |
| Max | 2 788.3 |
Other Multiples
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
